Access the world's leading financial data and tools

Subscribe for $2
Overview
Profile

Venus Medtech Hangzhou stock

2500.HK
CNE100003PJ8

Price

0
Today +/-
-0
Today %
-0 %

Venus Medtech Hangzhou stock price

%
Weekly
Details

Price

ⓘ

Overview

The Quote Chart provides detailed and dynamic insights into the Venus Medtech Hangzhou stock's performance, showcasing daily, weekly, or monthly aggregated quotes. Users can switch between different time frames to analyze the stock's progression meticulously and make informed investment decisions.

Intraday Feature

The intraday feature provides real-time data, allowing investors to view the Venus Medtech Hangzhou stock’s price fluctuations within the trading day, facilitating timely and strategic investment decisions.

Total Return and Relative Price Change

View the total return of the Venus Medtech Hangzhou stock to gauge its profitability over time. The relative price change, based on the first quote available in the selected timeframe, offers insights into the stock’s performance, assisting in evaluating its investment potential.

Interpretation and Investment

Utilize the comprehensive data presented in the Quote Chart to analyze Venus Medtech Hangzhou's market trends, price movements, and potential returns. Make informed investment choices by comparing different time frames and evaluating intraday data for optimized portfolio management.

Venus Medtech Hangzhou Stock Price History

DateVenus Medtech Hangzhou Price
12/31/20240 undefined
12/30/20240 undefined
12/27/20240 undefined
12/24/20240 undefined
12/23/20240 undefined
12/20/20240 undefined
12/19/20240 undefined
12/18/20240 undefined
12/17/20240 undefined
12/16/20240 undefined
12/13/20240 undefined
12/12/20240 undefined
12/11/20240 undefined
12/10/20240 undefined
12/9/20240 undefined
12/6/20240 undefined
12/5/20240 undefined

Venus Medtech Hangzhou Revenue, EBIT, Net Income

  • 3 years

  • 5 years

  • 10 years

  • 25 Years

  • Max

Revenue
EBIT
Net Income
Details

Revenue, EBIT and Profit

ⓘ

Understanding Revenue, EBIT, and Income

Gain insights into Venus Medtech Hangzhou, a comprehensive overview of its financial performance can be obtained by analyzing the Revenue, EBIT, and Income chart. Revenue represents the total income generated by Venus Medtech Hangzhou from its primary operations, showcasing the company’s ability to attract and retain clients. EBIT, or Earnings Before Interest and Taxes, indicates the company’s operational profitability, free from the influence of tax and interest expenses. The Income section reflects Venus Medtech Hangzhou’s net earnings, an ultimate measure of its financial health and profitability.

Yearly Analysis and Comparisons

Observe the yearly bars to understand the annual performance and growth of Venus Medtech Hangzhou. Compare the Revenue, EBIT, and Income to evaluate the company’s efficiency and profitability. A higher EBIT compared to the previous year suggests an improvement in operational efficiency. Likewise, an increase in Income indicates enhanced overall profitability. Analyzing the year-to-year comparison assists investors in understanding the company’s growth trajectory and operational efficiency.

Utilizing Expectations for Investment

The expected values for the forthcoming years offer investors a glimpse into Venus Medtech Hangzhou’s anticipated financial performance. Analyzing these projections alongside historical data aids in making informed investment decisions. Investors can gauge the potential risks and returns, aligning their investment strategies accordingly to optimize profitability and mitigate risks.

Investment Insights

Leveraging the comparison between Revenue and EBIT helps in assessing Venus Medtech Hangzhou’s operational efficiency, while the Revenue and Income comparison reveals the net profitability after accounting for all expenses. Investors can derive valuable insights by meticulously analyzing these financial parameters, laying the foundation for strategic investment decisions aimed at capitalizing on Venus Medtech Hangzhou’s growth potential.

Venus Medtech Hangzhou Revenue, EBIT and net profit per share

DateVenus Medtech Hangzhou RevenueVenus Medtech Hangzhou EBITVenus Medtech Hangzhou Net Income
2029e0 undefined0 undefined0 undefined
2028e0 undefined0 undefined0 undefined
2027e0 undefined0 undefined0 undefined
2026e0 undefined0 undefined0 undefined
2025e0 undefined0 undefined0 undefined
2024e0 undefined0 undefined0 undefined
20230 undefined0 undefined0 undefined
20220 undefined0 undefined0 undefined
20210 undefined0 undefined0 undefined
20200 undefined0 undefined0 undefined
20190 undefined0 undefined0 undefined
20180 undefined0 undefined0 undefined
20170 undefined0 undefined0 undefined

Venus Medtech Hangzhou Income Statement, Balance Sheet, Cash Flow Statement

  • Simple

  • Expanded

  • Income Statement

  • Balance Sheet

  • Cashflow

 
REVENUE (M)REVENUE GROWTH (%)GROSS MARGIN (%)GROSS INCOME (M)NET INCOME (M)NET INCOME GROWTH (%)SHARES (M)DOCUMENTS
20172018201920202021202220232024e2025e2026e2027e2028e2029e
0000000000000
-------------
-------------
0000000000000
0000000000000
-------------
0000000000000
-------------
Details

Keystats

ⓘ

Revenue and Growth

The Venus Medtech Hangzhou Revenue and Revenue Growth are pivotal to understanding the company's financial health and operational efficiency. A consistent increase in revenue indicates a company’s ability to effectively market and sell its products or services, while the revenue growth percentage offers insights into the pace at which the company is expanding over the years.

Gross Margin

The Gross Margin is a crucial metric that showcases the percentage of revenue exceeding the cost of goods sold (COGS). A higher gross margin is indicative of a company’s efficiency in controlling its production costs, thereby promising potential profitability and financial stability.

EBIT and EBIT Margin

EBIT (Earnings Before Interest and Taxes) and EBIT Margin offer deep insights into a company’s profitability, excluding the impacts of interest and taxes. Investors often assess these metrics to gauge the operational efficiency and inherent profitability of a business, separate from its financial structure and tax environment.

Income and Growth

Net Income and its subsequent growth are quintessential for investors looking to understand a company’s profitability. Consistent income growth underscores a company’s ability to enhance its profitability over time, reflecting operational efficiency, strategic competitiveness, and financial health.

Shares Outstanding

Shares outstanding refer to the total number of shares a company has issued. It's instrumental in calculating key metrics like Earnings Per Share (EPS) which is pivotal for investors to evaluate a company’s profitability on a per-share basis, offering a more granular view of financial health and valuation.

Interpreting Year to Year Comparison

Comparing yearly data allows investors to identify trends, assess the company’s growth, and anticipate potential future performance. Analyzing how metrics like revenue, income, and margins change year over year can provide valuable insights into the company’s operational efficiency, competitiveness, and overall financial health.

Expectations and Predictions

Investors often juxtapose the current and past financial data with the market’s expectations. This comparison aids in assessing whether the Venus Medtech Hangzhou is performing as anticipated, underperforming or outperforming the market predictions, providing pivotal data for investment decisions.

 
ASSETSCASH BALANCE (M)RECEIVABLES (M)OTHER REC. (M)INVENTORIES (M)OTHER CURRENT LIAB. (M)CURRENT ASSETS (M)TANGIBLE ASSETS (M)LONG-T. INVEST. (M)LONG-T. REC. (M)INTANGIBLE ASSETS (M)GOODWILL (M)OTHER NON-CURRENT ASSETS (M)NON-CURRENT ASSETS (M)TOTAL ASSETS (M)LIABILITIESCOMMON STOCK (M)ADDITIONAL PAID-IN CAPITAL (M)RETAINED EARNINGS (M)OTHER EQUITY (M)UNREAL. GAINS/LOSSES (M)EQUITY (M)LIABILITIES (M)PROVISIONS (M)OTHER SHORT-TERM LIAB. (M)SHORT-TERM DEBTS (M)LONG-TERM DEBT PORTION (M)SHORT-TERM REC. (M)LONG-T. LIAB. (M)DEFERRED TAXES (M)OTHER LIAB. (M)LONG-T. LIABILITIES (M)DEBT (M)TOTAL CAPITAL (M)
2017201820192020202120222023
             
0000000
0000000
0000000
0000000
0000000
0000000
0000000
0000000
0000000
0000000
0000000
0000000
0000000
0000000
             
0000000
0000000
0000000
0000000
0000000
0000000
0000000
0000000
0000000
0000000
0000000
0000000
0000000
0000000
0000000
0000000
0000000
0000000
Details

Balance Sheet

ⓘ

Understanding the Balance Sheet

The balance sheet of Venus Medtech Hangzhou provides a detailed financial snapshot, revealing the company's assets, liabilities, and equity at a specific point in time. Analyzing these components is crucial for investors looking to understand Venus Medtech Hangzhou's financial health and stability.

Assets

Venus Medtech Hangzhou's assets represent everything the company owns or controls that has monetary value. These are categorized into current and non-current assets, offering insights into the company's liquidity and long-term investments.

Liabilities

Liabilities are obligations that Venus Medtech Hangzhou must settle in the future. Analyzing the ratio of liabilities to assets provides insights into the company's financial leverage and risk exposure.

Equity

Equity refers to the residual interest in the assets of Venus Medtech Hangzhou after deducting liabilities. It represents the owners’ claim on the company’s assets and earnings.

Year-to-Year Analysis

Comparing balance sheet figures year-to-year allows investors to identify trends, growth patterns, and potential financial risks, facilitating informed investment decisions.

Interpreting the Data

Detailed analysis of assets, liabilities, and equity can provide investors with comprehensive insights into Venus Medtech Hangzhou's financial standing, aiding in investment evaluations and risk assessments.

 
NET INCOME (M)DEPRECIATION (M)DEFERRED TAXES (M)CHANGES IN WORKING CAPITAL (M)NON-CASH ITEM (M)PAID INTEREST (M)PAID TAXES (M)NET CASH FLOW FROM OPERATING ACTIVITIES (M)CAPITAL EXPENDITURES (M)CASH FLOW FROM INVESTING ACTIVITIES (M)CASH FLOW FROM OTHER INVESTING ACTIVITIES (M)INTEREST INCOME AND EXPENSES (M)NET DEBT CHANGE (M)NET CHANGE IN EQUITY (M)CASH FLOW FROM FINANCING ACTIVITIES (M)CASH FLOW FROM OTHER FINANCING ACTIVITIES ()TOTAL DIVIDENDS PAID (M)NET CHANGE IN CASH FLOW (M)FREE CASH FLOW (M)SHARE-BASED COMPENSATION (M)
201720182019202020212022
000000
000000
000000
000000
000000
000000
000000
000000
000000
000000
000000
000000
000000
000000
000000
------
000000
000000
000000
000000

Venus Medtech Hangzhou stock margins

The Venus Medtech Hangzhou margin analysis displays the gross margin, EBIT margin, as well as the profit margin of Venus Medtech Hangzhou. The EBIT margin (EBIT/sales) indicates the percentage of sales that remains as operating profit. The profit margin shows the percentage of sales that remains for Venus Medtech Hangzhou.

  • 3 years

  • 5 years

  • 10 years

  • 25 Years

  • Max

Gross margin
EBIT margin
Profit margin
Details

Margin

ⓘ

Understanding Gross Margin

The gross margin, expressed as a percentage, delineates the gross profit made from the Venus Medtech Hangzhou's sales revenue. A higher gross margin percentage indicates that the Venus Medtech Hangzhou retains more revenue after accounting for the costs of goods sold. Investors use this metric to gauge financial health and operational efficiency, as well as to compare it with competitors and industry averages.

EBIT Margin Analysis

EBIT margin represents the Venus Medtech Hangzhou's earnings before interest and taxes. Analyzing the EBIT margin over different years provides insights into the operational profitability and efficiency, excluding the effects of financial leverage and tax structure. A growing EBIT margin over the years signifies improving operational performance.

Revenue Margin Insights

The revenue margin demonstrates the Venus Medtech Hangzhou's total revenue generated. When comparing the revenue margin year over year, investors can gauge the Venus Medtech Hangzhou's growth and market expansion. It is essential to compare the revenue margin with the gross and EBIT margins to understand the cost and profit structures better.

Interpreting Expectations

The expected values for gross, EBIT, and revenue margins provide future financial outlook of the Venus Medtech Hangzhou. Investors should compare these expectations with historical data to understand potential growth and risk factors. It is crucial to consider the underlying assumptions and methodologies used in projecting these expected values to make informed investment decisions.

Comparative Analysis

Comparing the gross, EBIT, and revenue margins, both yearly and over multiple years, enables investors to perform a comprehensive analysis of the Venus Medtech Hangzhou's financial health and growth prospects. Evaluating the trends and patterns in these margins helps in identifying strengths, weaknesses, and potential investment opportunities.

Venus Medtech Hangzhou Margin History

Venus Medtech Hangzhou Gross marginVenus Medtech Hangzhou Profit marginVenus Medtech Hangzhou EBIT marginVenus Medtech Hangzhou Profit margin
2029e0 %0 %0 %
2028e0 %0 %0 %
2027e0 %0 %0 %
2026e0 %0 %0 %
2025e0 %0 %0 %
2024e0 %0 %0 %
20230 %0 %0 %
20220 %0 %0 %
20210 %0 %0 %
20200 %0 %0 %
20190 %0 %0 %
20180 %0 %0 %
20170 %0 %0 %

Venus Medtech Hangzhou Stock Sales Revenue, EBIT, Earnings per Share

The Venus Medtech Hangzhou earnings per share therefore indicates how much revenue Venus Medtech Hangzhou has generated per share in a given period. The earnings before interest and taxes per share shows how much of the operating profit corresponds to each share. The earnings per share indicates how much of the profit belongs to each share.

  • 3 years

  • 5 years

  • 10 years

  • 25 Years

  • Max

Sales per Share
EBIT per share
Earnings per Share
Details

Revenue, EBIT and Earnings per share

ⓘ

Revenue Per Share

Revenue per share represents the total revenue Venus Medtech Hangzhou earns, divided by the number of outstanding shares. It is a crucial metric as it reflects the company's ability to generate sales and signifies growth and expansion potential. Comparing yearly revenue per share allows investors to analyze the consistency in a company’s earnings and predict future trends.

EBIT Per Share

EBIT per share indicates Venus Medtech Hangzhou's earning before interest and taxes, offering insights into operational profitability excluding the effects of capital structure and tax rates. It can be juxtaposed against revenue per share to gauge the efficiency in converting sales into profits. A consistent increase in EBIT per share over the years underscores operational efficiency and profitability.

Income Per Share

Income per share, or earnings per share (EPS), reveals the portion of Venus Medtech Hangzhou’s profit allocated to each share of common stock. It’s instrumental in evaluating the profitability and financial health. By comparing it with revenue and EBIT per share, investors discern how effectively a firm translates sales and operational profits into net income.

Expected Values

Expected values are projections of revenue, EBIT, and income per share for forthcoming years. These anticipations, rooted in historical data and market analysis, aid investors in strategizing their investments, evaluating Venus Medtech Hangzhou's prospective performance, and estimating future stock prices. However, it’s pivotal to consider market volatilities and uncertainties that can influence these projections.

Venus Medtech Hangzhou Revenue, EBIT and net profit per share

DateVenus Medtech Hangzhou Sales per ShareVenus Medtech Hangzhou EBIT per shareVenus Medtech Hangzhou Earnings per Share
2029e0 undefined0 undefined0 undefined
2028e0 undefined0 undefined0 undefined
2027e0 undefined0 undefined0 undefined
2026e0 undefined0 undefined0 undefined
2025e0 undefined0 undefined0 undefined
2024e0 undefined0 undefined0 undefined
20230 undefined0 undefined0 undefined
20220 undefined0 undefined0 undefined
20210 undefined0 undefined0 undefined
20200 undefined0 undefined0 undefined
20190 undefined0 undefined0 undefined
20180 undefined0 undefined0 undefined
20170 undefined0 undefined0 undefined

Venus Medtech Hangzhou business model

Venus Medtech Hangzhou Inc. is a medical technology company specializing in the development, manufacturing, and marketing of minimally invasive heart valve implants. Venus Medtech Hangzhou is one of the most popular companies on Eulerpool.com.

Venus Medtech Hangzhou SWOT Analysis

Strengths

  • High-quality products and innovative medical technologies
  • Strong market presence and brand reputation
  • Robust financial position
  • Skilled and experienced workforce

Weaknesses

  • Limited global market reach
  • Relatively smaller size compared to some competitors
  • Dependence on key suppliers
  • Need for continuous research and development

Opportunities

  • Growing demand for minimally invasive medical procedures
  • Increasing aging population and prevalence of cardiovascular diseases
  • Expansion into new international markets
  • Strategic partnerships and collaborations for market growth

Threats

  • Intense competition from larger companies
  • Regulatory challenges and compliance requirements
  • Potential impact of economic slowdowns
  • Technological advancements by competitors
LIMITED TIME OFFER

The World’s Best Investors Are On Eulerpool

Subscribe for $2

Venus Medtech Hangzhou Eulerpool Fair Value

Details

Fair Value

ⓘ

Understanding Fair Value

The fair value of a stock provides insights into whether the stock is currently undervalued or overvalued. It is calculated based on profit, revenue, or dividends and offers a comprehensive perspective of the stock’s intrinsic value.

Income-Based Fair Value

This is calculated by multiplying the earnings per share by the average P/E ratio of the selected past years for smoothing. If the fair value is higher than the current market price, it suggests that the stock is undervalued.

Example 2022

Fair Value Profit 2022 = Earnings per Share 2022 / Average P/E Ratio 2019 - 2021 (3 Years Smoothing)

Revenue-Based Fair Value

It is derived by multiplying the revenue per share by the average price-to-sales ratio of the selected past years for smoothing. An undervalued stock is identified if the fair value exceeds the ongoing market price.

Example 2022

Fair Value Revenue 2022 = Revenue per Share 2022 / Average PSR 2019 - 2021 (3 Years Smoothing)

Dividend-Based Fair Value

This value is determined by dividing the dividend per share by the average dividend yield of the selected past years for smoothing. A higher fair value than the market price indicates an undervalued stock.

Example 2022

Fair Value Dividend 2022 = Dividend per Share 2022 * Average Dividend Yield 2019 - 2021 (3 Years Smoothing)

Expectations and Forecasts

Future expectations provide potential trajectories for stock prices and aid investors in decision-making. The expected values are forecasted figures of fair value, taking into account the growth or decline trends of profit, revenue, or dividend.

Comparative Analysis

Comparing the fair value based on profit, revenue, and dividend provides a holistic overview of the stock’s financial health. Observing the annual and per-annual variations contributes to understanding the consistency and reliability of stock performance.

Venus Medtech Hangzhou historical P/E ratio, EBIT multiple, and P/S ratio

LIMITED TIME OFFER

The World’s Best Investors Are On Eulerpool

Subscribe for $2

Venus Medtech Hangzhou shares outstanding

The number of shares was Venus Medtech Hangzhou in 2024 — This indicates how many shares 437.897 M is divided into. Since shareholders are the owners of a company, each share represents a small portion of the company's ownership.

  • 3 years

  • 5 years

  • 10 years

  • 25 Years

  • Max

Number of stocks
Details

Revenue, EBIT and Earnings per share

ⓘ

Revenue Per Share

Revenue per share represents the total revenue Venus Medtech Hangzhou earns, divided by the number of outstanding shares. It is a crucial metric as it reflects the company's ability to generate sales and signifies growth and expansion potential. Comparing yearly revenue per share allows investors to analyze the consistency in a company’s earnings and predict future trends.

EBIT Per Share

EBIT per share indicates Venus Medtech Hangzhou's earning before interest and taxes, offering insights into operational profitability excluding the effects of capital structure and tax rates. It can be juxtaposed against revenue per share to gauge the efficiency in converting sales into profits. A consistent increase in EBIT per share over the years underscores operational efficiency and profitability.

Income Per Share

Income per share, or earnings per share (EPS), reveals the portion of Venus Medtech Hangzhou’s profit allocated to each share of common stock. It’s instrumental in evaluating the profitability and financial health. By comparing it with revenue and EBIT per share, investors discern how effectively a firm translates sales and operational profits into net income.

Expected Values

Expected values are projections of revenue, EBIT, and income per share for forthcoming years. These anticipations, rooted in historical data and market analysis, aid investors in strategizing their investments, evaluating Venus Medtech Hangzhou's prospective performance, and estimating future stock prices. However, it’s pivotal to consider market volatilities and uncertainties that can influence these projections.

LIMITED TIME OFFER

The World’s Best Investors Are On Eulerpool

Subscribe for $2
Unfortunately, there are currently no price targets and forecasts available for Venus Medtech Hangzhou.

Venus Medtech Hangzhou latest earnings and earnings surprises

DateEPS EstimateEPS ActualQuarterly report
6/30/20240 0  (-12.39 %)2024 Q2
12/31/20230 0  (-41.24 %)2023 Q4
6/30/20230 0  (-17.06 %)2023 Q2
12/31/20220 0  (700.49 %)2022 Q4
6/30/20220 0  (-246.91 %)2022 Q2
12/31/20210 0  (-240.25 %)2021 Q4
6/30/20210 0  (-96.08 %)2021 Q2
12/31/20200 0  (-1,444.12 %)2020 Q4
12/31/20190 0  (-61.76 %)2019 Q4
1

Eulerpool ESG Scorecard© for the Venus Medtech Hangzhou stock

Eulerpool World ESG Rating (EESG©)

82/ 100

🌱 Environment

70

👫 Social

99

🏛️ Governance

78

Environment

Scope 1 - Direct Emissions
88.82
Scope 2 - Indirect emissions from purchased energy
4,020.62
Scope 3 - Indirect emissions within the value chain
Total CO₂ emissions
4,109.43
CO₂ reduction strategy
Coal energy
Nuclear power
Animal experiments
Fur & Leather
Pesticides
Palm Oil
Tobacco
Genetically modified organisms
Climate concept
Sustainable forestry
Recycling regulations
Environmentally friendly packaging
Hazardous substances
Fuel consumption and efficiency
Water consumption and efficiency

Social

Percentage of female employees56.9
Percentage of women in management
Percentage of Asian employees
Share of Asian management
Percentage of Hispanic/Latino employees
Hispano/Latino Management share
Percentage of Black employees
Black Management Share
Percentage of white employees
White Management Share
Adult content
Alcohol
Weapons
Firearms
Gambling
Military contracts
Human rights concept
Privacy concept
Occupational health and safety
Catholic

Governance (Corporate Governance)

Environmental reporting
Stakeholder Engagement
Call Back Policies
Antitrust law

The Eulerpool ESG Scorecard© is the strictly copyrighted intellectual property of Eulerpool Research Systems. Any unauthorized use, imitation, or infringement will be actively pursued and may lead to significant legal consequences. For licenses, collaborations, or usage rights, please contact us directly via our contact form. Contact Form to us.

Venus Medtech Hangzhou shareholders

%
Name
Stocks
Change
Date
12.93598 % Qiming Venture Partners57,048,980012/31/2023
7.71344 % Zi (Zhenjun)34,017,049012/31/2023
7.63058 % Zeng (Min)33,651,618012/31/2023
5.60390 % DCP Capital24,713,752012/31/2023
2.04188 % The Vanguard Group, Inc.9,004,87709/30/2024
1.62865 % ZhongGeng Fund Management Co., Ltd.7,182,50006/30/2024
1.58227 % Zhejiang Dinova Ruiying Venture Investment L.P.6,977,955012/31/2023
1.41777 % Bosera Asset Management Co., Ltd.6,252,50006/30/2024
0.80848 % Fidelity Management & Research (Hong Kong) Limited3,565,45908/31/2024
0.79397 % BlackRock Institutional Trust Company, N.A.3,501,50009/30/2024
1
2
3
4
5
...
9

Venus Medtech Hangzhou Executives and Management Board

Mr. Hou-Sen Lim

(50)
Venus Medtech Hangzhou Chief Operating Officer, Chief Technology Officer, General Manager, Joint Company Secretary (since 2016)
Compensation 1.26 M

Mr. Ting Yuk Wu

(69)
Venus Medtech Hangzhou Non-Executive Independent Chairman of the Board
Compensation 368,000

Mr. Chi Wai Suen

(59)
Venus Medtech Hangzhou Independent Non-Executive Director
Compensation 345,000

Ms. Liu Meirong

(47)
Venus Medtech Hangzhou Vice President, Executive Director (since 2023)

Mr. Ma Liqiao

(38)
Venus Medtech Hangzhou Executive Director (since 2023)
1
2

Most common questions regarding Venus Medtech Hangzhou

What values and corporate philosophy does Venus Medtech Hangzhou represent?

Venus Medtech Hangzhou Inc represents a strong set of values and corporate philosophy. With a focus on innovation and patient-centered care, the company strives to provide cutting-edge medical solutions. Venus Medtech Hangzhou Inc prioritizes quality, integrity, and transparency in all aspects of its business operations. With a passionate commitment to improving patient outcomes, the company nurtures a culture of excellence and collaboration. Venus Medtech Hangzhou Inc continuously advances its research and development efforts to create revolutionary cardiovascular technologies. As a result, the company has gained recognition for its dedication to harnessing the power of science and technology to enhance healthcare globally.

In which countries and regions is Venus Medtech Hangzhou primarily present?

Venus Medtech Hangzhou Inc is primarily present in China, where it is headquartered in Hangzhou City, Zhejiang Province. As a leading medical technology company, Venus Medtech has established a strong presence in various Chinese provinces and regions, including Beijing, Shanghai, Guangdong, and Jiangsu. With its innovative cardiac valve products and advanced medical solutions, Venus Medtech is also expanding its footprint globally. The company has successfully expanded into international markets such as Europe, especially in Germany, France, Italy, and the United Kingdom. Venus Medtech Hangzhou Inc continues to strive for further global expansion and enhancing patient care worldwide.

What significant milestones has the company Venus Medtech Hangzhou achieved?

Venus Medtech Hangzhou Inc has achieved several significant milestones. The company successfully developed and commercialized the Venus A-valve, a transcatheter aortic valve implantation (TAVI) system. This innovative product has revolutionized the treatment of aortic valve diseases, providing a less invasive option for patients. Venus Medtech also obtained the CE mark and the Chinese FDA approval for the Venus A-valve, expanding its market reach. The company's dedication to research and development led to the successful completion of clinical trials and collaborations with renowned medical institutions worldwide. With these achievements, Venus Medtech Hangzhou Inc has positioned itself as a global leader in cardiovascular medical devices.

What is the history and background of the company Venus Medtech Hangzhou?

Venus Medtech Hangzhou Inc is a leading medical device company specializing in innovative heart valve technologies. Established in Hangzhou, China, the company has a rich history of continuous improvement and breakthroughs in the field of cardiovascular health. Founded in [year], Venus Medtech has become a prominent player in the global medical device industry, providing life-saving solutions for patients with heart valve diseases. They are renowned for their expertise in transcatheter aortic valve replacement (TAVR) therapies, offering cutting-edge products that ensure improved clinical outcomes. With a strong commitment to research and development, Venus Medtech Hangzhou Inc has emerged as a trusted name in the global healthcare sector, revolutionizing the treatment of heart diseases.

Who are the main competitors of Venus Medtech Hangzhou in the market?

The main competitors of Venus Medtech Hangzhou Inc in the market are company A, company B, and company C.

In which industries is Venus Medtech Hangzhou primarily active?

Venus Medtech Hangzhou Inc is primarily active in the medical equipment industry. They specialize in developing and manufacturing innovative heart valve products, aiming to provide better treatment options for patients suffering from heart valve diseases. With their advanced technology and expertise in the field, Venus Medtech is committed to improving the quality of life for individuals in need of heart valve therapies. Their dedication to this industry has made them a leading company in the medical equipment market, continuously pushing boundaries and driving advancements in heart valve treatment solutions.

What is the business model of Venus Medtech Hangzhou?

Venus Medtech Hangzhou Inc operates under the business model of developing and commercializing medical devices for the treatment of structural heart diseases. Their focus is on the design, production, and distribution of transcatheter heart valve replacement systems. Venus Medtech strives to provide innovative and high-quality solutions that improve patient outcomes and enhance the quality of life for individuals with cardiovascular conditions. Through their commitment to research and development, clinical trials, and strategic partnerships, Venus Medtech aims to revolutionize the treatment options available for structural heart diseases.

What is the P/E ratio of Venus Medtech Hangzhou 2025?

The P/E ratio cannot be calculated for Venus Medtech Hangzhou at the moment.

What is the P/S ratio of Venus Medtech Hangzhou 2025?

The P/S cannot be calculated for Venus Medtech Hangzhou currently.

What is the Quality Investing of Venus Medtech Hangzhou?

The Quality Investing for Venus Medtech Hangzhou is 4/10.

What is the revenue of Venus Medtech Hangzhou 2025?

The revenue cannot currently be calculated for Venus Medtech Hangzhou.

How high is the profit of Venus Medtech Hangzhou 2025?

The profit cannot currently be calculated for Venus Medtech Hangzhou.

What is the business model of Venus Medtech Hangzhou

Venus Medtech Hangzhou Inc is a Chinese medical technology company that specializes in the development, manufacturing, and marketing of minimally invasive devices and products for cardiovascular diagnostics and intervention. The company offers a wide range of products, including coronary stents, peripheral stents, embolization materials, and transcatheter heart valves. Venus Medtech is a leading provider of coronary stents in China and has a growing presence internationally. The company has developed patented technologies to ensure improved performance and safety of their stents. They have also leveraged their expertise in minimally invasive procedures to develop a range of products for transkatheter heart valves. Additionally, Venus Medtech offers embolization therapy products for blocking blood vessels in various medical conditions. They work closely with leading clinics and specialists in the field of minimally invasive procedures and are dedicated to providing innovative technologies and products to meet the needs of their customers and patients. The company also provides training programs for medical professionals and has an active research and development department focused on advancing minimally invasive medicine. In summary, Venus Medtech Hangzhou Inc is a leading provider of minimally invasive devices and products for cardiovascular diagnostics and intervention, with a wide product range, patented technologies, and a dedicated research and development team.

What is the Venus Medtech Hangzhou dividend?

Venus Medtech Hangzhou pays a dividend of 0 CNY distributed over payouts per year.

How often does Venus Medtech Hangzhou pay dividends?

The dividend cannot currently be calculated for Venus Medtech Hangzhou or the company does not pay out a dividend.

What is the Venus Medtech Hangzhou ISIN?

The ISIN of Venus Medtech Hangzhou is CNE100003PJ8.

What is the Venus Medtech Hangzhou ticker?

The ticker of Venus Medtech Hangzhou is 2500.HK.

How much dividend does Venus Medtech Hangzhou pay?

Over the past 12 months, Venus Medtech Hangzhou paid a dividend of . This corresponds to a dividend yield of about . For the coming 12 months, Venus Medtech Hangzhou is expected to pay a dividend of 0 CNY.

What is the dividend yield of Venus Medtech Hangzhou?

The current dividend yield of Venus Medtech Hangzhou is .

When does Venus Medtech Hangzhou pay dividends?

Venus Medtech Hangzhou pays a quarterly dividend. This is distributed in the months of .

How secure is the dividend of Venus Medtech Hangzhou?

Venus Medtech Hangzhou paid dividends every year for the past 0 years.

What is the dividend of Venus Medtech Hangzhou?

For the upcoming 12 months, dividends amounting to 0 CNY are expected. This corresponds to a dividend yield of 0 %.

In which sector is Venus Medtech Hangzhou located?

Venus Medtech Hangzhou is assigned to the 'Health' sector.

Wann musste ich die Aktien von Venus Medtech Hangzhou kaufen, um die vorherige Dividende zu erhalten?

To receive the latest dividend of Venus Medtech Hangzhou from 1/3/2025 amounting to 0 CNY, you needed to have the stock in your portfolio before the ex-date on 1/3/2025.

When did Venus Medtech Hangzhou pay the last dividend?

The last dividend was paid out on 1/3/2025.

What was the dividend of Venus Medtech Hangzhou in the year 2024?

In the year 2024, Venus Medtech Hangzhou distributed 0 CNY as dividends.

In which currency does Venus Medtech Hangzhou pay out the dividend?

The dividends of Venus Medtech Hangzhou are distributed in CNY.

All fundamentals about Venus Medtech Hangzhou

Our stock analysis for Venus Medtech Hangzhou Revenue stock includes important financial indicators such as revenue, profit, P/E ratio, P/S ratio, EBIT, as well as information on dividends. We also assess aspects such as stocks, market capitalization, debt, equity, and liabilities of Venus Medtech Hangzhou Revenue. If you are looking for more detailed information on these topics, we offer comprehensive analyses on our subpages.